Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes
详细信息 查看全文
- 作者：Yutaka Onishi MD (1)
Takashi Fujisawa MD ; PhD (1)
Kazuhiko Sakaguchi MD ; PhD (1)
Mitsuo Maeda MD ; PhD (1) - 关键词：LDL particle size ; nateglinide ; insulin resistance ; postprandial hyperglycemia
- 刊名：Advances in Therapy
- 出版年：2006
- 出版时间：July 2006
- 年：2006
- 卷：23
- 期：4
- 页码：549-555
- 全文大小：194KB
- 参考文献：1. Koba S, Hirano T. Small dense low-density lipoprotein in Japanese men with coronary artery disease.Ann Intern Med. 2000;132:762.
2. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction.JAMA. 1988;260:1917-921. CrossRef
3. Yoshino G, Hirano T, Kazumi T. Treatment of small dense LDL.J Atheroscler Thromb. 2002; 9:266-75.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med. 1998;339:229-34. CrossRef
5. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.Arterioscler Thromb. 1992;12: 1496-502.
6. Hanefeld M, Fischer S, Julius U, et al. Risk factor for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up.Diabetologia. 1996;39: 1577-583. CrossRef
7. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnosis criteria.Lancet. 1999;354:617-21. CrossRef
8. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnosis criteria.Arch Intern Med. 2000;167:397-05.
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia. 1985;28:412-19. CrossRef
10. Tamasawa N, Matsui J, Ogawa Y, et al. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension.J Diabetes Complications. 2000;14:135-39. CrossRef
11. Miyashita Y, Iso Y, Hashiguchi S, et al. Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus.J Atheroscler Thromb. 2001;8:25-9.
12. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23).BMJ. 1998;316:823-28.
13. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.Diabetes Care. 2002;25:542-49. CrossRef
14. Austin MA, Edwards KL. Small dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes.Curr Opin Lipidol. 1996;7:167-71. CrossRef
15. McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotrophic agent.Clin Pharmacokinet. 2004;43:97-20. CrossRef
16. Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide—analysis based on the homeostasis model.Diabetes Res Clin Pract. 2003;62:87-4. CrossRef
17. Routolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezabibrate Coronary Atherosclerosis Intervention Trial (BACAIT).J Am Coll Cardiol. 1998;15:1648-656. CrossRef
18. Kazumi T, Kawaguchi A, Hozumi T, et al. Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men.Atherosclerosis. 1999;142:113-19. CrossRef
19. Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.Biol Pharm Bull. 2002;25:1412-416. CrossRef
20. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.Diabetes Metab Res Rev. 2002;18:484-90. CrossRef
21. Saloranta C, Lahti K, Guitard C, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.Diabetes Care. 2002;25:2141-146. CrossRef
22. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.Eur Heart J. 2004;25:10-6. CrossRef
23. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for The STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial.Lancet. 2002;359:2072-077. CrossRef
24. Mori Y, Kitahara Y, Miura K, Tajima N. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.Endocrine. 2004;23:39-3. CrossRef - 作者单位：Yutaka Onishi MD (1)
Takashi Fujisawa MD, PhD (1)
Kazuhiko Sakaguchi MD, PhD (1)
Mitsuo Maeda MD, PhD (1)
1. Department of Internal Medicine, Harima Hospital of Ishikawajima-Harima Heavy Industries, Health Insurance Society 3-5-15 Asahi, Aioi, 678-0031, Hyogo, Japan
文摘
The objective of the present study was to evaluate the efficacy of nateglinide in controlling blood glucose levels and regulating lipid metabolism in patients with type 2 diabetes by focusing attention particularly on low-density lipoprotein (LDL) particle size. The subjects were 23 patients with type 2 diabetes who were given nateglinide, 90 to 270 mg/d. Laboratory studies were conducted at treatment initiation and 3 mo later. Despite a decline that occurred in the level of fasting plasma glucose before and after administration of nateglinide, no significant difference was recognized. Hemoglobin A1c decreased significantly from 6.37±0.75% to 5.91±0.64% (P<.001). A significant decline was also seen in the fasting level of immunoreactive insulin, from 9.82±5.69 μU/mL to 8.59±4.05 μU/mL (P<.05), and in the homeostasis model assessment for insulin resistance, from 3.0±1.83 to 2.55±1.26 (P<.05). Regarding lipids, triglycerides significantly decreased from 140.7±61.8 mg/dL to 117.3±34.7 mg/dL (P<.05). The significant reduction in migration index value, which was used as an index to LDL particle size, from 0.374±0.034 to 0.357±0.035 (P<.05), confirmed that LDL particle size had increased. The results of the present study show that nateglinide is effective in controlling blood glucose and improving insulin resistance, hypertriglyceridemia, and LDL particle size in patients with mild type 2 diabetes. These effects suggest that nateglinide may effectively control coronary artery disease in this population.